Chemo Pharma Laboratories Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: February 24, 2025, 9:50 pm

Market Cap	12.2 Cr.
Current Price	81.1
High / Low	154/52.2
Stock P/E	30.4
Book Value	91.1
Dividend Yield	0.00 %
ROCE	13.3 %
ROE	9.67 %
Face Value	10.0
PEG Ratio	0.90

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Chemo Pharma Laboratories Ltd

Competitors of Chemo Pharma Laboratories Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.42 Cr.	3.88	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/30.8	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	39.3 Cr.	26.8	29.0/8.74	40.1	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	66.6 Cr.	88.4	155/81.2	10.8	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,027.01 Cr	1,068.45		42.50	185.19	0.37%	16.18%	16.43%	6.27

All Competitor Stocks of Chemo Pharma Laboratories Ltd

Quarterly Result

Metric	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Sales	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
Expenses	0.07	0.08	0.18	0.12	0.05	0.02	0.02	0.05	0.02	0.02	0.10	0.05	0.02
Operating Profit	-0.07	-0.08	-0.18	-0.12	-0.05	-0.02	-0.02	-0.05	-0.02	-0.02	-0.10	-0.05	-0.02
OPM %
Other Income	0.19	0.36	0.13	-0.38	0.59	0.19	-0.10	0.43	0.46	0.70	0.25	0.30	0.63
Interest	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
Depreciation	0.01	0.01	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
Profit before tax	0.11	0.27	-0.05	-0.50	0.54	0.17	-0.12	0.38	0.44	0.68	0.15	0.25	0.61
Tax %	-0.00%	-0.00%	-400.00%	-0.00%	-0.00%	-0.00%	25.00%	-0.00%	-0.00%	-0.00%	293.33%	-0.00%	-0.00%
Net Profit	0.11	0.28	0.14	-0.50	0.53	0.16	-0.15	0.38	0.44	0.68	-0.29	0.25	0.61
EPS in Rs	0.73	1.87	0.93	-3.33	3.53	1.07	-1.00	2.53	2.93	4.53	-1.93	1.67	4.07

Last Updated: January 5, 2025, 8:27 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Expenses	0.09	0.13	0.12	0.17	0.27	0.34	0.56	0.48	0.34	0.41	0.20	0.19	0.19
Operating Profit	-0.09	-0.13	-0.12	-0.17	-0.27	-0.34	-0.56	-0.48	-0.34	-0.41	-0.20	-0.19	-0.19
OPM %
Other Income	0.27	0.44	0.50	0.49	5.61	1.11	0.82	1.00	0.67	0.79	0.30	1.84	1.71
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00
Depreciation	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02	0.02	0.01	0.01	0.00
Profit before tax	0.17	0.31	0.38	0.32	5.34	0.77	0.26	0.50	0.31	0.36	0.08	1.64	1.52
Tax %	23.53%	19.35%	26.32%	31.25%	12.17%	85.71%	19.23%	16.00%	19.35%	-55.56%	37.50%	26.83%
Net Profit	0.14	0.24	0.28	0.22	4.68	0.10	0.21	0.42	0.25	0.56	0.05	1.20	1.08
EPS in Rs	0.93	1.60	1.87	1.47	31.20	0.67	1.40	2.80	1.67	3.73	0.33	8.00	7.20
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	71.43%	16.67%	-21.43%	2027.27%	-97.86%	110.00%	100.00%	-40.48%	124.00%	-91.07%	2300.00%
Change in YoY Net Profit Growth (%)	0.00%	-54.76%	-38.10%	2048.70%	-2125.14%	207.86%	-10.00%	-140.48%	164.48%	-215.07%	2391.07%

Chemo Pharma Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	%

Compounded Profit Growth
10 Years:	17%
5 Years:	41%
3 Years:	68%
TTM:	-70%

Stock Price CAGR
10 Years:	19%
5 Years:	62%
3 Years:	25%
1 Year:	10%

Return on Equity
10 Years:	4%
5 Years:	4%
3 Years:	5%
Last Year:	10%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 5:34 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50	1.50
Reserves	3.11	3.35	3.62	3.84	8.52	8.62	8.83	9.24	9.49	10.05	10.10	11.30	12.16
Borrowings	0.00	0.00	0.00	0.00	0.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.27	0.35	0.46	0.20	0.58	0.13	0.09	0.22	0.06	0.11	0.02	0.21	0.04
Total Liabilities	4.88	5.20	5.58	5.54	10.72	10.25	10.42	10.96	11.05	11.66	11.62	13.01	13.70
Fixed Assets	0.02	0.01	0.00	0.00	0.01	0.00	0.00	0.07	0.05	0.04	0.03	0.02	0.02
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	1.68	1.68	1.68	1.68	0.02	0.02	0.04	0.02	0.04	2.94	3.03	4.40	4.39
Other Assets	3.18	3.51	3.90	3.86	10.69	10.23	10.38	10.87	10.96	8.68	8.56	8.59	9.29
Total Assets	4.88	5.20	5.58	5.54	10.72	10.25	10.42	10.96	11.05	11.66	11.62	13.01	13.70

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	-0.39	-0.16	-0.05	-0.43	6.41	-1.66	-5.48	4.83	-0.41	-0.33	-0.68	0.72
Cash from Investing Activity +	0.22	0.13	0.25	0.49	0.52	1.08	0.79	1.01	-0.19	0.97	0.63	-0.52
Cash from Financing Activity +	-0.00	-0.00	-0.00	-0.00	-0.50	1.37	-0.00	-0.00	1.96	-2.12	-0.08	-0.15
Net Cash Flow	-0.17	-0.03	0.20	0.06	6.43	0.79	-4.70	5.84	1.36	-1.49	-0.13	0.05

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-0.09	-0.13	-0.12	-0.17	-0.39	-0.34	-0.56	-0.48	-0.34	-0.41	-0.20	-0.19

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days
Inventory Days
Days Payable
Cash Conversion Cycle
Working Capital Days
ROCE %	3.70%	6.55%	7.62%	6.12%	3.62%	7.60%	2.54%	4.75%	2.85%	1.33%	0.78%	13.28%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	27.89%	27.89%	27.89%	27.89%	27.88%	27.88%	27.88%	27.88%	27.88%	27.88%	27.88%	27.88%
DIIs	0.17%	0.17%	0.17%	0.17%	0.17%	0.17%	0.17%	0.17%	0.17%	0.17%	0.17%	0.17%
Public	71.95%	71.95%	71.95%	71.95%	71.94%	71.95%	71.95%	71.95%	71.95%	71.95%	71.94%	71.95%
No. of Shareholders	6,129	6,213	6,225	6,226	6,226	6,274	6,289	6,268	6,275	6,254	6,262	6,254

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 16
FaceValue	10.00
Basic EPS (Rs.)	-9.66
Diluted EPS (Rs.)	-9.66
Cash EPS (Rs.)	-9.66
Book Value[Excl.RevalReserv]/Share (Rs.)	24.49
Book Value[Incl.RevalReserv]/Share (Rs.)	24.49
PBDIT / Share (Rs.)	-8.98
PBIT / Share (Rs.)	-8.98
PBT / Share (Rs.)	-8.98
Net Profit / Share (Rs.)	-9.66
NP After MI And SOA / Share (Rs.)	-9.66
Return on Networth / Equity (%)	-39.44
Return on Capital Employeed (%)	-35.51
Return On Assets (%)	-37.44
Current Ratio (X)	28.82
Quick Ratio (X)	28.82
Enterprise Value (Cr.)	2.24
EV / EBITDA (X)	-1.66
Price / BV (X)	0.72
EarningsYield	-0.54

After reviewing the key financial ratios for Chemo Pharma Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 16, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
For Basic EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Diluted EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Cash EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 3. No previous period data is available for comparison.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
For PBDIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 2. No previous period data is available for comparison.
For PBIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
For PBT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
For Net Profit / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
For NP After MI And SOA / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
For Return on Networth / Equity (%), as of Mar 16, the value is -39.44. This value is below the healthy minimum of 15. No previous period data is available for comparison.
For Return on Capital Employeed (%), as of Mar 16, the value is -35.51. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For Return On Assets (%), as of Mar 16, the value is -37.44. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Current Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
For Quick Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
For Enterprise Value (Cr.), as of Mar 16, the value is 2.24. No previous period data is available for comparison.
For EV / EBITDA (X), as of Mar 16, the value is -1.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Price / BV (X), as of Mar 16, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
For EarningsYield, as of Mar 16, the value is -0.54. This value is below the healthy minimum of 5. No previous period data is available for comparison.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation. If you have any questions or need more detailed insights, please feel free to reach out.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Chemo Pharma Laboratories Ltd as of February 24, 2025 is: ₹218.53

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 24, 2025, Chemo Pharma Laboratories Ltd is Undervalued by 169.46% compared to the current share price ₹81.10

Intrinsic Value of Chemo Pharma Laboratories Ltd as of February 24, 2025 is: 292.71

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 24, 2025, Chemo Pharma Laboratories Ltd is Undervalued by 260.92% compared to the current share price ₹81.10

Last 5 Year EPS CAGR: 33.94%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a low average Working Capital Days of 0.00, which is a positive sign. The stock has a low average Cash Conversion Cycle of 0.00, which is a positive sign. The company has higher reserves (7.86 cr) compared to borrowings (0.01 cr), indicating strong financial stability.	The stock has a low average ROCE of 5.06%, which may not be favorable. The company has not shown consistent growth in sales (0.00) and profit (0.92).

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemo Pharma Laboratories Ltd:
1. Net Profit Margin: 0%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: -35.51% (Industry Average ROCE: 16.05%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -39.44% (Industry Average ROE: 15.89%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 0
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 28.82
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 30.4 (Industry average Stock P/E: 34.42)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Chemo Pharma Laboratories Ltd. is a Public Limited Listed company incorporated on 17/08/1942 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1942PLC003556 and registration number is 003556. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 0.00 Cr. and Equity Capital is Rs. 1.50 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	5, Kumud Apartment CHS Ltd., Thane District Maharashtra 421301	chemopharmalab@gmail.com http://www.thechemopharmalaboratoriesltd.com

Management
Name	Position Held
Mr. Bhavin Sheth	Executive Director & CEO
Mr. Ashok Somani	Executive Director & CFO
Mrs. Shanta Somani	Non Executive Director
Mr. Mathura Prasad Sharma	Independent Director
Mr. Toby Antony	Independent Director
Mr. Nandkumar Pareek	Independent Director

FAQ

What is the latest intrinsic value of Chemo Pharma Laboratories Ltd?

Let's break down Chemo Pharma Laboratories Ltd's intrinsic value simply:

We calculate intrinsic value using the PE Ratio Method - comparing the company's current price-to-earnings ratio with its historical average and industry peers. Think of it like checking if a stock is "on sale" compared to its typical pricing.

As of 24 February 2025:

Calculated Fair Value: ₹218.53
Current Market Price: ₹81.10
Variance: 169.46% higher

This suggests Chemo Pharma Laboratories Ltd is currently undervalued by 169.46%. For context:

Market Cap: 12.2 Cr.
52-Week Range: 154/52.2
Reserves (Sep 2024): ₹12.16 Cr
Liabilities: 13.70 Cr

Remember: The PE method gives a snapshot based on earnings multiples. While useful for quick comparisons, investors should also consider growth prospects, industry trends, and economic conditions. This calculation assumes historical PE ratios remain relevant - always verify with current market dynamics.

What is the Market Cap of Chemo Pharma Laboratories Ltd?

The Market Cap of Chemo Pharma Laboratories Ltd is 12.2 Cr..

What is the current Stock Price of Chemo Pharma Laboratories Ltd as on 24 February 2025?

The current stock price of Chemo Pharma Laboratories Ltd as on 24 February 2025 is ₹81.1.

What is the High / Low of Chemo Pharma Laboratories Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Chemo Pharma Laboratories Ltd stocks is 154/52.2.

What is the Stock P/E of Chemo Pharma Laboratories Ltd?

The Stock P/E of Chemo Pharma Laboratories Ltd is 30.4.

What is the Book Value of Chemo Pharma Laboratories Ltd?

The Book Value of Chemo Pharma Laboratories Ltd is 91.1.

What is the Dividend Yield of Chemo Pharma Laboratories Ltd?

The Dividend Yield of Chemo Pharma Laboratories Ltd is 0.00 %.

What is the ROCE of Chemo Pharma Laboratories Ltd?

The ROCE of Chemo Pharma Laboratories Ltd is 13.3 %.

What is the ROE of Chemo Pharma Laboratories Ltd?

The ROE of Chemo Pharma Laboratories Ltd is 9.67 %.

What is the Face Value of Chemo Pharma Laboratories Ltd?

The Face Value of Chemo Pharma Laboratories Ltd is 10.0.